彭布罗利珠单抗
医学
乳腺癌
内科学
肿瘤科
转移性乳腺癌
化疗
炎症性乳腺癌
癌症
免疫疗法
作者
Toshiaki Iwase,Evan N. Cohen,Hui Gao,Angela Alexander,Megumi Kai,Vivian Chiv,Xiaoping Wang,Savitri Krishnamurthy,Diane D. Liu,Yu Shen,Kumiko Kida,Alexandre Reuben,Rachel M. Layman,David L. Ramírez,Debasish Tripathy,Stacy L. Moulder,Clinton Yam,Vicente Valero,Bora Lim,James M. Reuben,Naoto T. Ueno
标识
DOI：10.1158/1078-0432.ccr-23-2947
摘要
Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy of maintenance immunotherapy in patients with metastatic HER2-negative inflammatory breast cancer (IBC) and non-IBC triple-negative breast cancer (TNBC) and a biomarker study.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
你嵙这个期刊没买
无极微光
大力的灵雁
ephore
小小
带头大哥
eric888
麦子
干净的琦
dew
ZJH
pcr163
Whim
杨华启
蓝莓橘子酱
LinaTang
QVQ
今天你查文献了吗
tiptip
穆清
皖公网安备34019202002308
